Dupixent® (dupilumab) Receives U.S. Approval for Treating Chronic Rhinosinusitis with Nasal Polyps in Adolescents
Sep 14, 2024
Regeneron Invest Information
Regeneron Showcases Respiratory Treatments at ERS 2024 Congress
Aug 26, 2024
Innovative COPD Therapy Dupixent Gains Approval in the EU, Marking a First for Targeted Treatment
Jul 4, 2024
Intellia Therapeutics Surpasses Q3 Earnings Expectations and Announces Progress in Gene-Editing Pipeline
Nov 11, 2023